PeptaHub
The comprehensive peptide reference
SKIN & BEAUTYPEPTIDE PROFILE

Argireline

Also known as Acetyl Hexapeptide-8, Acetyl Hexapeptide-3, Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2

Argireline (Acetyl Hexapeptide-8) is a synthetic hexapeptide used topically to reduce the appearance of expression lines and wrinkles. It is a fragment of SNAP-25, a protein involved in neurotransmitter vesicle docking, and is marketed as a topical alternative to botulinum toxin injections. It is one of the most studied cosmetic signal peptides.

Last updated April 10, 2026

CITATION PACKET

Cite this answer

STABLE ANSWER BLOCK · #answer

Argireline: quick citable summary

Argireline is listed by PeptaHub as a skin & beauty peptide with a unregulated legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.

HOW TO CITE · CC BY 4.0

PeptaHub. “Argireline: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/argireline. Licensed CC BY 4.0.

License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/argireline.

QUICK ANSWER

What is Argireline?

Argireline (Acetyl Hexapeptide-8) is a topical cosmetic peptide that reduces expression wrinkles by interfering with SNARE complex formation. A 10 percent emulsion reduced wrinkle depth by up to 30 percent over 30 days, and a 60-subject randomised trial found benefit over placebo at 4 weeks.

§ 01

Overview

Argireline (Acetyl Hexapeptide-8) is a synthetic hexapeptide used topically to reduce the appearance of expression lines and wrinkles. It is a fragment of SNAP-25, a protein involved in neurotransmitter vesicle docking, and is marketed as a topical alternative to botulinum toxin injections. It is one of the most studied cosmetic signal peptides.

§ 02

Mechanism of action

Argireline competitively inhibits the formation of the SNARE complex — the protein assembly responsible for synaptic vesicle fusion and acetylcholine release at the neuromuscular junction. By mimicking the N-terminal portion of SNAP-25, it interferes with catecholamine secretion and reduces repetitive facial muscle contractions that cause dynamic wrinkles. Unlike botulinum toxin, which cleaves SNAP-25 irreversibly, Argireline's inhibition is reversible and topically limited, with no systemic neuromuscular blockade observed at cosmetic concentrations.

§ 03

Reported study ranges

PurposeRouteReported rangeFrequency
wrinkle reductiontopical510 %twice daily

Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.

Convert Argireline research-range units

Need to convert mg to mcg, dose volume, or U-100 syringe units? Use the peptide dose unit converter for educational calculation support.

§ 04

Research summary

Two human studies underpin the anti-wrinkle claim, and neither reports the figures usually quoted for Argireline. Blanes-Mira (Int J Cosmet Sci 2002) applied a 10 percent oil-in-water emulsion to healthy women volunteers and reported wrinkle depth reduced by up to 30 percent after 30 days; that arm was not placebo-controlled. Wang (Am J Clin Dermatol 2013) randomised 60 Chinese subjects 3:1 to argireline or placebo for peri-orbital wrinkles over 4 weeks and reported total anti-wrinkle efficacy of 48.9 percent on subjective assessment versus 0 percent for placebo, with roughness parameters decreased on silicone-replica analysis. Blanes-Mira also reported no oral toxicity and no primary irritation at high doses in vivo. No published human study has measured systemic absorption of Argireline, so its absence is untested rather than demonstrated.[1][2][3][4][5]

📄This section cites 5 peer-reviewed sources. View all references →
§ 04b

Evidence grading

Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.

moderate
Topical wrinkle depth reductionBlanes-Mira Int J Cosmet Sci 2002: 10 percent emulsion on healthy women volunteers, wrinkle depth down up to 30 percent at 30 days, not placebo-controlled. Wang Am J Clin Dermatol 2013: randomised placebo-controlled, n=60, 4 weeks, 48.9 percent subjective anti-wrinkle efficacy versus 0 percent placebo. Two small short studies
moderate
SNARE complex inhibition mechanismBlanes-Mira 2002: demonstrated SNAP-25 N-terminal mimicry and reversible SNARE assembly disruption; established cell-based mechanism
moderate
Cosmetic safety (non-toxic, non-comedogenic)Blanes-Mira 2002 reported no in vivo oral toxicity and no primary irritation at high doses; Grosicki Acta Biochim Pol 2014 assessed cytotoxicity in cell culture. Supported by long post-market cosmetic use, but no dedicated human safety trial is cited here
moderate
Visible improvement in expression linesHenseler GMS Interdiscip Plast Reconstr Surg DGPW 2023: Visia imaging assessment of a hyaluronic acid serum containing Argireline. Imaging study without a placebo arm, so it cannot separate the peptide from the vehicle
insufficient
Equivalence to injectable botulinum toxinMechanism is reversible and far less potent than Botox; no head-to-head RCT vs injectable neurotoxins

Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data

§ 05

Side effects

Generally well tolerated
Mild skin irritation (rare)
Redness at application site (rare)

Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.

§ 06

Common stacks

Peptides commonly paired with Argireline for synergistic effects.

§ 08

Sourcing & access

Research compound

Argireline is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).

§ 09

Frequently asked questions

Argireline (Acetyl Hexapeptide-8) is a synthetic cosmetic peptide that reduces expression lines and wrinkles when applied topically. It works by interfering with the SNARE protein complex that enables muscle contraction, similar in concept to botulinum toxin but far less potent and fully reversible.

Argireline works through a related mechanism but is far less potent. Botulinum toxin irreversibly cleaves SNAP-25; Argireline interferes with formation of the SNARE complex and inhibited neurotransmitter release with a potency similar to botulinum toxin A but much lower efficacy in the original characterisation. The human results are modest by comparison: up to 30 percent wrinkle depth reduction after 30 days of a 10 percent emulsion, and 48.9 percent subjective anti-wrinkle efficacy versus 0 percent placebo in a 60-subject 4-week trial. No head-to-head study against injectable botulinum toxin exists.

The published trials ran 30 days at 10 percent (Blanes-Mira 2002) and 4 weeks twice daily (Wang 2013), so effects within roughly a month are what the evidence supports. No published study has tested what happens after discontinuation, so claims about how quickly wrinkle depth rebounds are unsourced.

The original characterisation reported no oral toxicity and no primary irritation at high doses in vivo (Blanes-Mira 2002), and a later cell-culture study examined its cytotoxicity (Grosicki 2014). Reported side effects in use are limited to mild skin irritation or redness at the application site. No published human study has measured systemic absorption or neurological endpoints, so the absence of those effects is untested rather than demonstrated. It is regulated as a cosmetic rather than a drug.

Argireline is commonly combined with Matrixyl for structural collagen support, GHK-Cu for tissue remodeling, SYN-AKE for additional expression line reduction through a different neuromuscular pathway, and Palmitoyl Tetrapeptide-7 for anti-inflammatory effects. These multi-peptide serums target both dynamic and static wrinkles through complementary mechanisms across SNARE inhibition, matrix remodeling, and inflammation control.

§ 10

Research references

  1. A synthetic hexapeptide (Argireline) with antiwrinkle activityBlanes-Mira C, Clemente J, Jodas G, et al.International Journal of Cosmetic Science, 2002PubMed
  2. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled studyWang Y, Wang M, Xiao S, Pan P, et al.American Journal of Clinical Dermatology, 2013PubMed
  3. The study of cellular cytotoxicity of argireline - an anti-aging peptideGrosicki M, Latacz G, Szopa A, Cukier A, et al.Acta Biochimica Polonica, 2014PubMed
  4. Argireline: Needle-Free Botox as Analytical ChallengeKluczyk A, Ludwiczak J, Modzel M, Kuczer M, et al.Chemistry & Biodiversity, 2021PubMed
  5. Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia® Complexion Analysis camera system for objective skin analysisHenseler HGMS Interdisciplinary Plastic and Reconstructive Surgery DGPW, 2023PubMed
● READER REVIEWS

What readers say about Argireline

No reader reviews yet. If you’ve used Argireline, share your experience — your review helps the next person decide.